Cancer Genetics CEO Moderates Panel Discussion With Thought Leaders in Biopharma at the BioNJ 2014 International BioPartnering Conference

  • Panna Sharma, CEO of Cancer Genetics, Is Moderating a Panel Entitled "Partnering for a Balanced Portfolio: Perspectives from Innovators, Partners, & Payers"

RUTHERFORD, N.J., April 10, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an emerging leader in DNA-based cancer diagnostics, announced that the Company is a sponsor of the BioNJ International BioPartnering Conference where Panna Sharma will be moderating a panel on the topic of "Partnering for a Balanced Portfolio: Perspectives from Innovators, Partners, and Payers" today Thursday, April 10, 2014 at the Westin Princeton at Forrestal Village.

"Delivering in today's life sciences and healthcare environment requires partnerships, cross-disciplinary work, and integrating teams across companies," said Panna Sharma, Chief Executive Officer of Cancer Genetics. "The insight that our panel of experts at this morning's BioNJ conference brings into the critical issues of portfolio development, selection and partnerships is remarkable. Collaborations between established pharmaceutical companies and smaller companies with strong R&D and breakthrough technology or insight have long been a feature of the industry. As new drug candidates become more targeted, and global markets become even more accessible we expect to see more partnerships both between companies and across industries to ensure that portfolios have depth, are balanced, and very productive."

Details of the Panel Presentation

Date: Thursday, April 10, 2014
Time: 9:00 am – 9:45 am
Location: The Westin Princeton at Forrestal Village
201 Village Blvd, Princeton, NJ
Panel Title: Building a Balanced Portfolio

This panel includes key executives from pharma, biotech, and corporate venture partners who will be discussing the latest trends / landscape in partnering, alliance models, and their company's strategy to capture external innovations.

  • Moderator: Panna Sharma, President & CEO, Cancer Genetics, Inc.
  • Simon J. Archibald, PhD, Chief Scientist, Integra LifeSciences Corporation
  • Iain D. Dukes, D Phil, SVP, MRL Licensing & External Scientific Affairs, Merck
  • Brenda D. Gavin, DVM, MBA, Founding Partner, Quaker Partners
  • Michael Gutch, PhD, Managing Director, MedImmune Ventures

About BioNJ

BioNJ's mission is to advance the biotechnology and biotechnology-related industries in New Jersey for the benefit of the citizens, the economy and patients of New Jersey, the US and worldwide. BioNJ accomplishes its mission through excellence in: Ensuring the acquisition and availability of appropriate human, capital, and other resources necessary for building successful biotechnology and biotechnology support companies in the State; Formulating and advocating policy positions to elected officials, regulators, the media and general public; and, Enhancing global awareness and appreciation of New Jersey's talent, experience and resources.

About Cancer Genetics:

Cancer Genetics, Inc. is an emerging leader in DNA-based cancer diagnostics, servicing some of the most prestigious medical institutions in the world. Our tests target cancers that are difficult to diagnose and predict treatment outcomes. These cancers include hematological, urogenital and HPV-associated cancers. We also offer a comprehensive range of non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals, as well as biopharma and biotech companies. Our state-of-the-art reference lab is focused entirely on maintaining clinical excellence and is both CLIA certified and CAP accredited and has licensure from several states including New York State. We have established strong research collaborations with major cancer centers such as Memorial Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National Cancer Institute. For further information, please see

Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development and potential opportunities for Cancer Genetics, Inc. products and services, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to, statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, risks of cancellation of customer contracts or discontinuance of trials, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, maintenance of intellectual property rights and other risks discussed in the Company's Form 10-K for the year ended December 31, 2013 and other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Cancer Genetics disclaims any obligation to update these forward-looking statements.

CONTACT: Investor Relations Michael Rice Life Science Advisors LLC 646-597-6979 Media Relations RedChip Companies, Inc. Paul Kuntz, 800-733-2447, ext. 105 paul@redchip.comSource:Cancer Genetics